HRMY - Harmony Biosciences to acquire Zynerba for up to $200M in cash
2023-08-14 08:01:42 ET
More on Zynerba
- Zynerba says not holding cash deposits or securities at Silicon Valley Bank
- Zynerba delaying release of late-stage top-line results for Fragile X syndrome candidate
- Zynerba rises on orphan drug status for cannabidiol Zygel for 22q11.2 deletion syndrome in EU
- Zynerba gets US patent for cannabidiol Zygel to treat 22q11.2 Deletion Syndrome
- Seeking Alpha’s Quant Rating on Zynerba Pharmaceuticals
For further details see:
Harmony Biosciences to acquire Zynerba for up to $200M in cash